Merit Medical Systems, Inc. (NASDAQ:MMSI) Shares Acquired by Principal Securities Inc.

Principal Securities Inc. lifted its position in shares of Merit Medical Systems, Inc. (NASDAQ:MMSI) by 28.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,342 shares of the medical instruments supplier’s stock after purchasing an additional 513 shares during the period. Principal Securities Inc.’s holdings in Merit Medical Systems were worth $227,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Farther Finance Advisors LLC lifted its position in shares of Merit Medical Systems by 32.7% during the third quarter. Farther Finance Advisors LLC now owns 1,056 shares of the medical instruments supplier’s stock worth $104,000 after purchasing an additional 260 shares in the last quarter. Harvest Fund Management Co. Ltd acquired a new position in shares of Merit Medical Systems during the third quarter worth $120,000. GAMMA Investing LLC lifted its position in shares of Merit Medical Systems by 14.7% during the fourth quarter. GAMMA Investing LLC now owns 1,494 shares of the medical instruments supplier’s stock worth $144,000 after purchasing an additional 191 shares in the last quarter. TD Private Client Wealth LLC lifted its position in shares of Merit Medical Systems by 13.9% during the third quarter. TD Private Client Wealth LLC now owns 1,732 shares of the medical instruments supplier’s stock worth $171,000 after purchasing an additional 211 shares in the last quarter. Finally, Sanctuary Advisors LLC bought a new stake in shares of Merit Medical Systems in the third quarter worth $207,000. 99.66% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on MMSI. Needham & Company LLC lifted their price target on shares of Merit Medical Systems from $109.00 to $122.00 and gave the stock a “buy” rating in a research note on Wednesday, January 29th. Barrington Research lifted their price target on shares of Merit Medical Systems from $114.00 to $115.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 29th. Piper Sandler restated an “overweight” rating and issued a $116.00 price target (up previously from $114.00) on shares of Merit Medical Systems in a research note on Wednesday, January 29th. StockNews.com lowered shares of Merit Medical Systems from a “buy” rating to a “hold” rating in a research note on Sunday, November 3rd. Finally, Robert W. Baird lifted their price target on shares of Merit Medical Systems from $107.00 to $109.00 and gave the stock an “outperform” rating in a research note on Thursday, October 31st. Two investment analysts have rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $109.80.

Merit Medical Systems Stock Performance

MMSI stock opened at $103.16 on Monday. The company has a market capitalization of $6.01 billion, a P/E ratio of 50.57, a PEG ratio of 2.34 and a beta of 0.87. The company has a 50-day simple moving average of $102.64 and a 200 day simple moving average of $99.64. Merit Medical Systems, Inc. has a fifty-two week low of $70.70 and a fifty-two week high of $111.45. The company has a quick ratio of 3.82, a current ratio of 5.36 and a debt-to-equity ratio of 0.57.

Merit Medical Systems Company Profile

Merit Medical Systems, Inc designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions.